Two leases on LIF

How Northern targets both tumor immunosuppression and self-renewal

While most immuno-oncology products in the clinic target the immunosuppressive factors that help tumors evade an attack, Northern Biologics Inc.'s anti-LIF antibody takes a step further. By simultaneously blocking both immunosuppression and self-renewal of cancer stem cells the newco expects the antibody to be effective against a wider range of cancers than other immuno-oncology programs.

Northern was launched in 2014 by Versant Ventures to develop cancer and fibrosis

Read the full 678 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers